您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Pertuzumab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Pertuzumab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:380610-27-5
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议
100mg电议

产品名称
帕妥株单抗
产品介绍
Pertuzumab 是一种人源化 IgG1 单克隆抗体,是一种HER2二聚抑制剂。可用于转移性HER2 阳性乳腺癌的研究。
生物活性

Pertuzumab, a humanizedIgG1monoclonal antibody, is aHER2dimerization inhibitor for the treatment of metastatic HER2-positive breastcancer.

IC50& Target

HER2

 

体外研究
(In Vitro)

Trastuzumab and Pertuzumab are highly synergistic inhibitors of BT474 breast cancer cell survival. The combination of trastuzumab and Pertuzumab mediates a loss of up to 60% of cells at doses in which individual drugs do not alter cell survival. The combination of trastuzumab and Pertuzumab reduces the percentage of proliferating (S-phase) cells by more than 2-fold. A combination of trastuzumab and Pertuzumab inhibits cell proliferation and survival to a greater degree than does either agent alone[1].

体内研究
(In Vivo)

In Calu-3 NSCLC xenografts, monotherapy with pertuzumab or trastuzumab is able to significantly inhibit tumor growth, with treatment-to-control ratios (TCR) of 0.23 and 0.27, respectively. The combination of trastuzumab and pertuzumab produces a dramatically enhanced antitumor activity compared with single-agent treatments (TCR 0.05, resulting in tumor regression and, in 3 of 10 animals, complete tumor remission). Treatment of KPL-4 breast cancer xenografts with either trastuzumab or pertuzumab inhibits tumor growth with TCRs of 0.67 and 0.65, respectively. Pertuzumab maintains antitumor activity after progression on trastuzumab[2].

Clinical Trial
分子量

145175.18

性状

Liquid

CAS 号

380610-27-5

中文名称

帕妥株单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.